- The Short Answer
- Where ARA-290 Comes From
- How ARA-290 Works in Research
- What Researchers Are Studying ARA-290 For
- How ARA-290 Differs From Erythropoietin
- Frequently Asked Questions
The Short Answer
ARA-290 is a short synthetic peptide (a small chain of amino acids built in a laboratory) that researchers study for its ability to reduce inflammation and protect nerve tissue. It was designed by modifying a small region of erythropoietin, a hormone the body naturally produces to stimulate red blood cell production. The modified version is studied specifically for its effects on the immune system and nervous system, without the red blood cell side effects of the original hormone.
Where ARA-290 Comes From
To understand what is ARA-290, it helps to start with the hormone it is based on: erythropoietin, usually abbreviated as EPO.
EPO is a hormone produced mainly by the kidneys. Its primary job is to signal the bone marrow to make more red blood cells. Doctors have used synthetic versions of EPO for decades to treat conditions like anemia (a shortage of red blood cells).
Researchers studying EPO noticed something interesting: the hormone seemed to do more than just stimulate red blood cell production. It also appeared to have protective effects on cells throughout the body, including nerve cells. But using full EPO to study these effects came with a major drawback. It also caused the body to produce more red blood cells, which can raise the risk of blood clots and other cardiovascular complications.
This led scientists to ask a key question: could they isolate just the protective part of EPO’s activity, without triggering the red blood cell effects?
ARA-290 was the result of that effort. Scientists identified a specific segment of the EPO molecule that appeared responsible for its tissue-protective and anti-inflammatory properties, then synthesized a small peptide based on that segment. The result is a compound that, in laboratory settings, activates a different set of cellular signals than standard EPO does, without stimulating red blood cell production.
ARA-290 is also sometimes referred to by the name cibinetide in more recent research literature.
How ARA-290 Works in Research
Every cell in the body has proteins on its surface called receptors. You can think of receptors like locks, and molecules like ARA-290 like keys. When the right key fits the right lock, it triggers a response inside the cell.
Standard erythropoietin binds to one type of receptor that triggers red blood cell production. ARA-290 is designed to bind to a different receptor complex: one that researchers call the innate repair receptor, or IRR. This receptor is found on many types of cells throughout the body, particularly in tissues involved in immune responses and in nerve cells.
When ARA-290 binds to this receptor in laboratory settings, it appears to activate internal pathways inside the cell that reduce inflammation and help protect the cell from damage or death. Inflammation is the body’s normal response to injury or threat, but when it becomes excessive or chronic (ongoing for a long time), it can damage surrounding tissue, including nerves.
Research in cell cultures and animal models has focused on how ARA-290 interacts with this receptor system and what downstream effects that interaction produces. Studies have examined whether this binding activity can reduce the kind of chronic, damaging inflammation associated with nerve injury and certain metabolic conditions.
The innate repair receptor pathway is an active area of study. Researchers are working to better understand exactly which signals it activates and why those signals appear to differ from the ones EPO triggers through its primary receptor. The full picture of how ARA-290 produces its studied effects is still being established.
What Researchers Are Studying ARA-290 For
The primary areas of investigation for ARA-290 center on two overlapping themes: nerve protection and inflammation reduction.
Nerve damage and neuropathy. Neuropathy refers to damage or dysfunction in the peripheral nervous system, the network of nerves that runs outside the brain and spinal cord, connecting the brain to the limbs and organs. Conditions like diabetes can cause this kind of nerve damage over time. Researchers have studied ARA-290 in animal models of peripheral neuropathy to examine whether its activation of the innate repair receptor influences nerve cell survival and function. Some early-stage human studies have also examined ARA-290 in this context, though clinical research remains at an early phase.
Systemic inflammation. Chronic, low-level inflammation underlies many conditions, and researchers have used ARA-290 as a tool to study the innate repair receptor pathway’s role in regulating inflammatory responses. In animal models and early human studies, researchers have looked at markers of inflammation to understand whether ARA-290 influences them.
Metabolic conditions. Because inflammation and nerve function are both involved in metabolic diseases, some research has examined ARA-290 in models involving insulin sensitivity and related processes. This line of investigation is early-stage and largely preclinical (conducted in animals and cell cultures rather than large human trials).
Other research peptides studied in overlapping areas include BPC-157, TB-500, and Semax, each of which researchers investigate through different mechanisms. ARA-290’s research is distinctive for its focus on the innate repair receptor as a specific target. For a broader look at how peptide research addresses immune-related questions, the Immune System Support Peptide Research guide covers a range of compounds studied in this space.
How ARA-290 Differs From Erythropoietin
One of the most common points of confusion for people who first encounter ARA-290 is understanding how it relates to EPO. They share a connection, but they are quite different compounds with different research profiles.
Size. Erythropoietin is a large protein with 165 amino acids (the building blocks of proteins). ARA-290 is a small peptide containing only 11 amino acids. This smaller size affects how the compound behaves in research settings, including how it moves through tissues and how long it remains active.
Receptor target. EPO’s primary job is activating the EPO receptor, which stimulates red blood cell production. ARA-290 is designed to target the innate repair receptor instead. This is the fundamental difference that researchers use to study tissue-protective effects without the blood-related activity.
Research purpose. EPO is an approved medication used clinically for anemia. ARA-290 is strictly a research compound: it is not approved for any medical use, and all studies involving it are conducted under research settings only. It is classified as a research-use-only compound, meaning it is available exclusively for laboratory and scientific research.
Side effect profile in research. Because ARA-290 does not activate the primary EPO receptor, studies have not observed the red blood cell stimulation that makes high-dose EPO concerning. This makes ARA-290 a useful research tool for isolating the tissue-protective aspects of EPO-related biology without those confounding effects.
For a deeper look at the compound’s full research profile, the ARA-290 complete research guide covers mechanisms, study findings, and the current state of the evidence in more detail. The Cenexa Labs Peptide Research Library also covers related research areas including neurodegenerative conditions, inflammation, and metabolic health.
Frequently Asked Questions
What does ARA-290 stand for?
ARA-290 is a research designation assigned to the compound during its development. It is also known as cibinetide, which became the more common name as clinical research progressed. Both names refer to the same compound: a synthetic 11-amino acid peptide derived from a region of the erythropoietin molecule.
Is ARA-290 the same as EPO?
No, ARA-290 and EPO (erythropoietin) are different compounds. ARA-290 is a small synthetic peptide derived from a specific segment of EPO, but it targets a different receptor and does not stimulate red blood cell production. Researchers study ARA-290 specifically because it separates the tissue-protective properties of EPO from its blood-forming effects.
Is ARA-290 approved for medical use?
ARA-290 is not approved for medical use by the FDA or any other regulatory authority. It is classified as a research-use-only compound, meaning it is available solely for laboratory and scientific research. All studies involving ARA-290 are conducted under controlled research conditions and are not intended as clinical treatment.
What is the innate repair receptor?
The innate repair receptor is a protein complex found on the surface of many cell types, including immune cells and nerve cells. Researchers believe it plays a role in the body’s natural tissue repair processes. ARA-290 is studied specifically because it appears to activate this receptor, which is different from the receptor that standard erythropoietin activates for red blood cell production.
What kinds of research have studied ARA-290?
ARA-290 has been studied in cell cultures, animal models, and some early-phase human trials. Research has focused primarily on peripheral neuropathy (nerve damage), chronic inflammation, and metabolic conditions. The compound is used as a research tool to understand the innate repair receptor pathway, and clinical research remains at early stages.
Where can I find more information about peptide research like ARA-290?
The Cenexa Labs Peptide Research Library covers a wide range of research peptides and the biological systems they target. Related areas of research include neurodegenerative disease, immune function, and inflammation biology. All content in the library is written for educational and research purposes only.
